Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia

Drugs in R and D

Volumn 6, Issue 4, 2005, Pages 207-219

  Castano G ^a   Fernandez L ^a   Mas, R ^a   Illnait, J ^a   Gamez R ^a   Mendoza, S ^a   Mesa, M ^a   Fernandez J ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; POLICOSANOL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEARTBURN; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FATTY ALCOHOLS; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; TRIGLYCERIDES;

EID: 22244482805     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200506040-00003     Document Type: Article

References (53)

1. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in the incidence of coronary heart disease. JAMA 1984; 251: 351-64
2. Lipid Research Clinic Program. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in the incidence of coronary heart disease to cholesterol-lowering. JAMA 1984; 251: 365-74
3. Frick MH, Elo O, Happa K. Helsinki Heart Study: primary-prevention with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-45
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S): Lancet 1994; 344: 1383-9
5. Sacks FM, Pfeffer MA, Moyé LA, et al. for the Cholesterol and Recurrent Events Trial Investigators: the effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
6. The Long-Term Intervention with pravastatin in ischaemic Dis-ease (LIPID) Study Group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
7. Shepherd S, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
8. Downs JR, Clearfield M, Weiss S, et al. for the AFCAPS/ TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22
10. Shepherd J, Blauw GJ, Murphy MB, et al. on behalf of the PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled study. Lancet 2002; 360: 1623-30
11. Expert Panel of Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
12. Gotto AM, Assman G, Carmena R, et al. The ILIB lipid hand-book for clinical practice. Blood lipids and coronary heart disease. 2nd ed. New York: International Lipid Information Bureau (ILIB), 2000
13. Mas R. Policosanol. Drugs of the Future 2000; 25: 569-86
14. Ortensi G, Gladstein H, Valli H, et al. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res 1997; 58: 390-401
15. Mas R, Castaño G, Illnait J, et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1998; 65: 439-47
16. Castaño G, Más R, Arruzazabala ML, et al. Effects of policosanol, pravastatin on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients. Int J Clin Pharmacol Res 1999; 19: 105-16
17. Castãno G, Más R, Fernández L, et al. Effect of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 2000; 13: 187-95
18. Mas R, Castaño G, Fernández L, et al. Effects of policosanol in older hypercholesterolemic patients with coronary disease. Clin Drug Invest 2001; 21: 485-97
19. Castaño G, Mas R, Fernández L, et al. Comparison of the efficacy, safety and tolerability of policosanol versus atorvastatin in elderly patients with type II hypercholesterolemia. Drugs Aging 2003; 20: 153-63
20. Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 1995; 18: 393-7
21. Crespo N, Illnait J, Mas R, et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and non insulin dependent diabetes mellitus. Int J Clin Pharmacol Res 1999; 19: 105-16
22. Castaño G, Fernández L, Mas R, et al. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidemia and type 2 diabetes mellitus. Clin Drug Invest 2003; 23: 639-50
23. Menéndez R, Fernández I, Del Río A, et al. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol Res 1994; 27: 199-203
24. Menéndez R, Arruzazabala ML, Más R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starchcasein diet. Br J Nutr 1996; 77: 923-32
25. Menéndez R, Amor A, Rodeiro I, et al. Policosanol modulates HMGCoA reductase activity in cultured fibroblasts. Arch Med Res 2001; 32: 8-12
26. Arruzazabala ML, Valdés S, Más R, et al. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Pharmacol Res 1996; 34: 181-5
27. Arruzazabala ML, Más R, Molina V, et al. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients. Int J Tissue React 1998; 20: 119-24
28. Menéndez R, Más R, Amor AM, et al. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol 2000; 50: 255-62
29. Menéndez R, Más R, Amor A, et al. Effects of policosanol on the low density lipoprotein (LDL) isolated on hypercholesterolemic patients at high coronary risk to in vitro copper-mediated lipid peroxidation: a randomised, double-blinded pilot study. Curr Ther Res 2000; 61: 609-20
30. Gámez R, Alemán CL, Mas R, et al. A 6-month study on the toxicity of high doses of policosanol orally administered to Sprague Dawley rats. J Med Food 2001; 4: 57-66
31. Mesa AR, Más R, Noa M, et al. Toxicity of policosanol in beagle dogs: one year study. Toxicol Lett 1994; 73: 81-90
32. Rodríguez MD, García H. Teratogenic and reproductive studies of policosanol in the rat and rabbit. Teratog Carcinog Mutagen 1994; 14: 107-13
33. Alemán CL, Más R, Noa M, et al. Carcinogenicity of policosanol in Sprague Dawley rats: a 24 month study. Teratog Carcinog Mutagen 1994; 14: 239-49
34. Harris WS, Park Y, Isley WL. Cardiovascular disease and long chain omega-3 fatty acids. Curr Opin Lipidol 2003; 14: 9-14
35. Lee KW, Lip GV. The role of omega-3 fatty acids in the secondary prevention of cardiovascular disease. QJM 2003; 96: 465-80
36. Richtner WO. Long-chain omega-3 fatty acids from fish reduce sudden cardiac death in patients with coronary heart disease. Eur J Med Res 2003; 8: 332-6
37. Lemaitre RN, King IB, Mozaffarian D, et al. n-3 Polyunsaturated fatty acids, fatal ischemic heart disease and non fatal myocardial infarction in older adults: the Cardiovascular Health Study. Am J Clin Nutr 2003; 77: 319-25
38. Hu FB, Bronner L, Willett WC, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 2002; 287: 1815-21
39. De Caterina R, Madonna R, Zucchi R, et al. Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside. Am Heart J 2003; 146: 420-30
40. Mori TA, Beilin LJ. Long-chain omega 3 fatty acids, blood lipids and cardiovascular reduction. Curr Opin Lipidol 2001; 12: 11-7
41. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996; 100: 197-204
42. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45
43. Seigler L, Wu WT. Separation of serum high-density lipoprotein for cholesterol determination: ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin Chem 1981; 27: 838-41
44. Friedewald WT, Levy IR, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
45. Suzukawa M, Abbey M, Howe PRC, et al. Effects of fish oil fatty acids on low-density lipoprotein size, oxidizability, and uptake by macrophages. J Lipid Res 1995; 36: 473-84
46. Harris W. Fish oil and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 1989; 30: 785-807
47. Nestel PJ. Effects of n-3 fatty acids on lipid metabolism. Annu Rev Nutr 1990; 10: 149-67
48. Sandset PM, Lund H, Norseth J, et al. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in components of the extrinsic coagulation system. Arterioscler Thromb Vasc Biol 1991; 11: 138-45
49. Contacos C, Barter PJ, Sullivan DR. Effect of pravastatin and omega 3 fatty acids on plasma lipids and lipoproteins patients with combined hyperlipidaemia. Arterioscler Thromb 1993; 13: 1755-62
50. Nordoy A, Bonaa KH, Nilsen H, et al. Effects of simvastatin and omega 3 fatty acids on plasma lipoprotein and lipid peroxidation in patients with combined hyperlipidaemia. J Intern Med 1998; 243: 163-70
51. Durrington PN, Bhatnagar D, Mackness MI, et al. The effects of an omega-3 fatty polyunsaturated acid concentrate administered for one year to simvastatin treated patients with established coronary artery disease and persisting hypertriglyceridemia. Heart 2001; 85: 544-8
52. Chan DC, Watts GF, Barrett HR, et al. Effect of atorvastatin and fish oil on plasma high-sensitivity Creactive protein concentrations in individuals with visceral obesity. Clin Chem 2002; 48: 877-83
53. Bhatnagar D, Mackness MI, Durrington PN. Treatment of mixed hyperlipidaemia using a combination of omega-3 fatty acids and HMGCoA reductase inhibitors. Eur Heart J Suppl 2001; Suppl. D: D53-8